These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17051670)

  • 1. [How many harmed by rofecoxib in Germany?].
    Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I
    Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670
    [No Abstract]   [Full Text] [Related]  

  • 2. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
    Mühlbauer B; Timm J
    Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
    [No Abstract]   [Full Text] [Related]  

  • 3. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 4. Balancing the cyclooxygenase portfolio.
    Armstrong PW
    CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse cardiovascular effects of rofecoxib.
    Furberg CD
    N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442
    [No Abstract]   [Full Text] [Related]  

  • 6. [Rofecoxib increases myocardial infarction risk in seniors].
    Wasielewski S
    Med Monatsschr Pharm; 2005 Nov; 28(11):416-7. PubMed ID: 16309032
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse cardiovascular effects of rofecoxib.
    Nissen SE
    N Engl J Med; 2006 Jul; 355(2):203-4; author reply 203-5. PubMed ID: 16801355
    [No Abstract]   [Full Text] [Related]  

  • 8. Observational studies and the withdrawal of rofecoxib.
    Watson DJ; Santanello NC
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998
    [No Abstract]   [Full Text] [Related]  

  • 9. COX-2 selective inhibitors and heart health.
    Simon LS; White WB
    Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of cardiovascular risk after rofecoxib discontinuation.
    Ross JS; Madigan D; Konstam MA; Egilman DS; Krumholz HM
    Arch Intern Med; 2010 Dec; 170(22):2035-6. PubMed ID: 21149763
    [No Abstract]   [Full Text] [Related]  

  • 11. [Assessment of the number of cardio- and cerebrovascular events due to rofecoxib (Vioxx) in Germany between 2001 and 2004].
    Sawicki PT; Bender R; Selke GW; Klauber J; Gutschmidt S
    Med Klin (Munich); 2006 Mar; 101(3):191-7. PubMed ID: 16648975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
    Bäck M; Yin L; Ingelsson E
    Eur Heart J; 2012 Aug; 33(15):1928-33. PubMed ID: 22108833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?].
    Brune K; Zacher J
    MMW Fortschr Med; 2004 Oct; 146(42):10, 12. PubMed ID: 15536697
    [No Abstract]   [Full Text] [Related]  

  • 14. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
    Sukel MP; van der Linden MW; Chen C; Erkens JA; Herings RM
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):9-19. PubMed ID: 17963198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac risks with COX-2 inhibitors.
    Ashworth AJ
    CMAJ; 2007 Feb; 176(4):489-92. PubMed ID: 17296963
    [No Abstract]   [Full Text] [Related]  

  • 16. The withdrawal of rofecoxib.
    Arellano FM
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
    [No Abstract]   [Full Text] [Related]  

  • 17. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
    Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
    Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The patient's perspective on the recall of Vioxx.
    Hawker GA; Katz JN; Solomon DH
    J Rheumatol; 2006 Jun; 33(6):1082-8. PubMed ID: 16755654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.